Skip to main content
. Author manuscript; available in PMC: 2011 Jan 21.
Published in final edited form as: Shock. 2009 Jun;31(6):621–626. doi: 10.1097/SHK.0b013e31818bbe21

Fig. 6. rFXIIIa protects from thrombin-induced HUVEC resistance alterations.

Fig. 6

Transendothelial electrical resistance of HUVECs after the following types of treatment is shown: 0.1 nM thrombin, 50 nM rFXIIIa, combination of thrombin and rFXIIIa, or albumin (control). Data are expressed as means ± SE (n = 8 in each group). Human umbilical vein endothelial cell resistance after thrombin administration (starting from 0.5 h after treatment) is lower than in all other groups (P < 0.05). Human umbilical vein endothelial cell resistance after thrombin + rFXIIIa administration (starting from 0.5 h and up to 1.2 h after treatment) is higher than after sole thrombin administration alone but lower than after sole rFXIIIa treatment or albumin administration (P < 0.05).